Bundibugyo Virus Outbreak Response Vaccines (BundiVx) - RRPV Consortium
Overview
Buyer
Place of Performance
NAICS
PSC
Set Aside
Original Source
Timeline
Qualification Details
Fit reasons
- NAICS alignment with historical contract wins in similar service areas.
- Scope strongly matches core technical capabilities and delivery model.
Risks
- Past performance thresholds may require one additional teaming partner.
- Potential clarification needed on staffing minimums before bid/no-bid.
Next steps
Validate eligibility requirements, assign capture owner, and schedule partner outreach to confirm teaming strategy before submission planning.
Quick Summary
The Office of Biomedical Advanced Research and Development Authority (BARDA), within the U.S. Department of Health and Human Services (HHS), seeks proposals through the Rapid Response Partnership Vehicle (RRPV) Consortium for the Bundibugyo Virus Outbreak Response Vaccines (BundiVx) initiative. The purpose is to advance investigational Bundibugyo ebolavirus (BDBV) vaccine candidates leveraging the VSV vaccine platform. The end goal is to produce cGMP clinical trial material (CTM) and meet regulatory requirements to enable use of investigational candidates in a clinical trial for the ongoing 2026 BDBV outbreak, and to identify successful BDBV vaccine candidates for further development. This effort anticipates approximately $75 million for 1-3 awards.
Scope of Work
This Request for Project Proposals (RPP) requires offerors to advance VSV-based BDBV vaccine candidates. Key activities include:
- Manufacturing: Process development through production of initial cGMP Phase 1 CTM (up to 10,000 doses), with an option for up to 100,000 doses. This involves process development, analytical assay development, and qualification.
- Nonclinical Studies: IND-enabling studies to support Phase 1 Investigational New Drug (IND) submission.
- Clinical Trial: Planning and execution of a Phase 1 safety and immunogenicity study under a U.S. FDA IND.
- Regulatory: Support for regulatory submissions to the U.S. FDA, including IND applications.
- Outbreak Support: Potential for production of up to 100,000 doses of CTM and logistical support for outbreak response.
Contract Details
- Type: Other Transaction Agreement (OTA) through the Rapid Response Partnership Vehicle (RRPV) Consortium.
- Period of Performance: Anticipated up to five (5) years from the date of award.
- Estimated Funding: Approximately $75 million anticipated for 1-3 awards.
- Set-Aside: None specified (eligibility requires RRPV membership).
- Product/Service Code: AN23 - Health R&D Services; Health Research And Training; Experimental Development.
- Agency: Department of Health and Human Services (HHS), Office of Biomedical Advanced Research and Development Authority (BARDA).
Eligibility & Submission
- Eligibility: Offerors must be RRPV members at the time of proposal submission. The proposed approach must use a VSV-based platform technology, and the developer and proposed CDMO must have a demonstrated manufacturing relationship. Gain-of-function research is prohibited.
- Submission Portal: Proposals must be submitted via www.RRPV.HHS.gov (requires a BDR Portal account).
- Questions Due: June 16, 2026, by 12 p.m. Eastern.
- Proposals Due: June 26, 2026, by 1 p.m. Eastern.
Evaluation
Award will be based on evaluation criteria including Technical Approach, Relevant Corporate and Capabilities Experience, Program Management Approach, and Cost/Price. Technical factors are weighted more heavily than cost/price.